Quadrant Capital Group LLC Vir Biotechnology, Inc. Transaction History

Quadrant Capital Group LLC

  • $1.42 Billion
  • Q3 2024

A detailed history of Quadrant Capital Group LLC transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Quadrant Capital Group LLC holds 3,326 shares of VIR stock, worth $24,612. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,326
Previous 4,102 18.92%
Holding current value
$24,612
Previous $36,000 33.33%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$7.26 - $10.7 $5,633 - $8,303
-776 Reduced 18.92%
3,326 $24,000
Q2 2024

Aug 12, 2024
SELL
$7.63 - $12.66 $20,120 - $33,384
-2,637 Reduced 39.13%
4,102 $36,000
Q1 2024

May 15, 2024
BUY
$8.6 - $11.9 $32,413 - $44,851
3,769 Added 126.9%
6,739 $68,000
Q4 2023

Feb 08, 2024
BUY
$7.76 - $10.29 $16,893 - $22,401
2,177 Added 274.53%
2,970 $29,000
Q3 2023

Nov 14, 2023
BUY
$9.14 - $24.62 $1,754 - $4,727
192 Added 31.95%
793 $7,000
Q2 2023

Aug 09, 2023
SELL
$23.2 - $27.29 $31,482 - $37,032
-1,357 Reduced 69.31%
601 $14,000
Q1 2023

May 11, 2023
BUY
$22.26 - $30.85 $31,230 - $43,282
1,403 Added 252.79%
1,958 $45,000
Q4 2022

Feb 10, 2023
SELL
$19.96 - $28.22 $8,283 - $11,711
-415 Reduced 42.78%
555 $14,000
Q3 2022

Nov 10, 2022
BUY
$18.26 - $31.1 $10,499 - $17,882
575 Added 145.57%
970 $19,000
Q2 2022

Aug 09, 2022
BUY
$19.08 - $26.7 $6,181 - $8,650
324 Added 456.34%
395 $10,000
Q1 2022

May 06, 2022
BUY
$21.19 - $40.01 $805 - $1,520
38 Added 115.15%
71 $2,000
Q4 2021

Feb 01, 2022
SELL
$30.97 - $54.03 $1,114 - $1,945
-36 Reduced 52.17%
33 $1,000
Q3 2021

Nov 12, 2021
BUY
$34.9 - $54.54 $2,233 - $3,490
64 Added 1280.0%
69 $3,000
Q2 2021

Aug 09, 2021
BUY
$38.75 - $51.0 $193 - $255
5 New
5 $0

Others Institutions Holding VIR

# of Institutions
218
Shares Held
87M
Call Options Held
127K
Put Options Held
1.19M
View Full List

About Vir Biotechnology, Inc.

VIR Quotes by TradingView
  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $982M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Quadrant Capital Group LLC Portfolio

Follow Quadrant Capital Group LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email